The Latest Updates from ReSPECT Clinical Trials
Plus Therapeutics Treats First Patients in ReSPECT-LM Dose Optimization Trial for Leptomeningeal Metastases
Plus Therapeutics is pleased to announce that the first patients have been treated in the ReSPECT-LM dose optimization clinical trial, evaluating REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of leptomeningeal metastases (LM)—a devastating and often...
Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for Leptomeningeal Metastases
Plus Therapeutics is pleased to announce the initiation of the ReSPECT-LM dose optimization clinical trial for REYOBIQ™ (rhenium Re 186 obisbemeda), a radiotherapeutic designed to target and treat leptomeningeal metastases (LM)—a devastating complication of metastatic...
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments....
Plus Therapeutics Receives FDA Clearance for New Pediatric Brain Cancer Clinical Trial: ReSPECT-PBC
We are proud to announce that the U.S. Food and Drug Administration (FDA) has officially cleared Plus Therapeutics’ Investigational New Drug (IND) application for REYOBIQ™, a novel radiotherapeutic under development for the treatment of pediatric patients with...
FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial
FDA Clears IND for Plus Therapeutics' REYOBIQ™ in Pediatric Brain Cancer Trial Plus Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has officially cleared its Investigational New Drug (IND) application for REYOBIQ™, a targeted...
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
We are proud to highlight one of Plus Therapeutics’ leading Principal Investigators, Andrew Brenner, M.D., Ph.D., who recently appeared on KABB News to speak with Melissa Vega about the challenges and advancements in treating glioblastoma (GBM) — one of the most...
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...
Plus Therapeutics CEO Marc Hedrick, M.D., Discusses the Future of Oncology Innovation in New Interview
At Plus Therapeutics, our mission is rooted in innovation, precision, and the pursuit of better outcomes for patients facing some of the most aggressive and difficult-to-treat cancers. In a recent interview with AlphaStreet, our President and CEO, Marc Hedrick, M.D.,...
Spotlight on Leadership: Dr. Toral Patel, Principal Investigator for the RESPECT-GBM Clinical Trial
At Plus Therapeutics, advancing treatment for patients with recurrent glioblastoma (GBM) requires collaboration with some of the brightest minds in brain cancer research and neurosurgery. Today, we’re proud to feature one of our esteemed RESPECT-GBM Principal...
Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial
Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial As part of our ongoing commitment to highlight the incredible medical professionals behind the ReSPECT-GBM clinical trial, today we are proud to...
Advancing Hope on Brain Tumor Awareness Day: Plus Therapeutics and Game On Glio Unite for Glioblastoma Patients
Each year, Brain Tumor Awareness Day serves as a critical reminder of the challenges faced by brain cancer patients, and the urgent need for continued research, innovation, and advocacy. At Plus Therapeutics, we are proud to stand alongside passionate individuals and...
Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation
Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation Today is Brain Tumor Awareness Day—a day dedicated to raising awareness for those affected by brain tumors and honoring the patients, caregivers, and advocates working...
June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches
June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches Following Brain Cancer Awareness Month, June marks Brain and Spine Metastasis Awareness Month, a critical time to raise awareness about the...
New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner
New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner A new article by Ariana Pelosci at Cancer Network highlights promising data from Plus Therapeutics’ ongoing Phase 1/2 ReSPECT-GBM clinical trial, which is...
Honoring National Gray Day: Advancing Brain Cancer Awareness and Research
Honoring National Gray Day: Advancing Brain Cancer Awareness and Research Today marks National Gray Day, a powerful observance during Brain Cancer Awareness Month dedicated to honoring the lives lost to brain cancer and standing in solidarity with patients, survivors,...
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast In case you missed it, Plus Therapeutics President and CEO Dr. Marc Hedrick recently joined Ayesha Rashid on the Xtalks Life Sciences Podcast to discuss the company’s...
NMN Symposium 2025
New Data on REYOBIQ™ for Leptomeningeal Metastases Presented at the NMN Conference! Plus Therapeutics is pleased to announce that new clinical data on its lead investigational therapy, REYOBIQ™ (rhenium Re 186 obisbemeda), was presented at the Nuclear Medicine and...
Brain Cancer Awareness Month 2025
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
“A New Way to Treat Brain Cancer?”
REYOBIQ™ Clinical Trial for Recurrent Glioma Featured in Oncolytics Today We’re proud to share that Plus Therapeutics’ innovative work on REYOBIQ™ (rhenium-186 Re obisbemeda) has been featured as the cover story in the latest issue of Oncolytics Today, published by...
NMN 2025 Abstract Announcement
Plus Therapeutics to Present New REYOBIQ™ Clinical Data at Nuclear Medicine Symposium 2025 We’re excited to announce that Plus Therapeutics will present new data on our lead radiotherapeutic compound, REYOBIQ™ (rhenium Re186 obisbemeda), at the upcoming Nuclear...
Contents
- 1 The Latest Updates from ReSPECT Clinical Trials
- 1.1 Plus Therapeutics Treats First Patients in ReSPECT-LM Dose Optimization Trial for Leptomeningeal Metastases
- 1.2 Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for Leptomeningeal Metastases
- 1.3 Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
- 1.4 Plus Therapeutics Receives FDA Clearance for New Pediatric Brain Cancer Clinical Trial: ReSPECT-PBC
- 1.5 FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial
- 1.6 Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
- 1.7 Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
- 1.8 Plus Therapeutics CEO Marc Hedrick, M.D., Discusses the Future of Oncology Innovation in New Interview
- 1.9 Spotlight on Leadership: Dr. Toral Patel, Principal Investigator for the RESPECT-GBM Clinical Trial
- 1.10 Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial
- 1.11 Advancing Hope on Brain Tumor Awareness Day: Plus Therapeutics and Game On Glio Unite for Glioblastoma Patients
- 1.12 Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation
- 1.13 June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches
- 1.14 New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner
- 1.15 Honoring National Gray Day: Advancing Brain Cancer Awareness and Research
- 1.16 Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast
- 1.17 NMN Symposium 2025
- 1.18 Brain Cancer Awareness Month 2025
- 1.19 “A New Way to Treat Brain Cancer?”
- 1.20 NMN 2025 Abstract Announcement